VolitionRx Closes $13.8 Million Public Offering

Represented VolitionRx in its $13.8 million public offering of common stock.  VolitionRx is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases.